p53 is associated with high-risk and pinpointsTP53missense mutations in mantle cell lymphoma

Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not benefit from modern chemotherapy-based treatments and have poor prognosis. Thus, there is a clinical need to identify mis...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2020-12, Vol.191 (5), p.796
Main Authors: Rodrigues, Joana M., Hassan, May, Freiburghaus, Catja, Eskelund, Christian W., Geisler, Christian, Raty, Riikka, Kolstad, Arne, Sundström, Christer, Glimelius, Ingrid, Gronbaek, Kirsten, Kwiecinska, Anna, Porwit, Anna, Jerkeman, Mats, Ek, Sara
Format: Article
Language:English
Subjects:
digital pathology
immunohistochemistry
mantle cell lymphoma
p53
styled-content style="text-decoration
targeted sequencing
underline">TP53
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not benefit from modern chemotherapy-based treatments and have poor prognosis. Thus, there is a clinical need to identify missense mutations through routine analysis to enable patient stratification. Sequencing is not widely implemented in clinical practice for MCL, and immunohistochemistry (IHC) is a feasible alternative to identify high-risk patients. The aim of the present study was to investigate the accuracy of p53 as a tool to identify patients withTP53missense mutations and the prognostic impact of overexpression and mutations in a Swedish population-based cohort. In total, 317 cases were investigated using IHC and 255 cases were sequenced, enabling analysis of p53 andTP53status among 137 cases divided over the two-cohort investigated. The accuracy of predicting missense mutations from protein expression was 82%, with sensitivity at 82% and specificity at 100% in paired samples. We further show the impact of p53 expression andTP53mutations on survival (hazard ratio of 3 center dot 1 in univariate analysis for both), and the association to risk factors, such as high MCL International Prognostic Index, blastoid morphology and proliferation, in a population-based setting.
ISSN:1365-2141
0007-1048
DOI:10.1111/bjh.17023